Shilhav Meisel Sharon received her B.Sc. degree in Biotechnology from Bar Ilan University, Ramat Gan. She completed her Master’s Degree in the Department of Anatomy, Sackler School of Medicine, Tel Aviv University. Shilhav’s M.Sc. project dealt with the characterization of a new Wnt/b-catenin signaling activator – aldolase C. Currently, Shilhav is a Ph.D. student in Prof. Haim Werner’s laboratory. Her main field of interest is the mechanism of action of the TMPRSS2-ERG fusion protein in prostate cancer. TMPRSS2-ERG is a chimeric protein that results from recurrent chromosomal translocations in prostate cancer and which leads to over expression of the ERG oncogene in the prostate. Studies performed over the last ten years have shown that TMPRSS2-ERG has a major role in prostate cancer etiology. Using a combination of molecular and biochemical methods, Shilhav has recently identified the IGF1R gene as a novel downstream target for TMPRSS2-ERG action.
Email: shilhav.m@gmail.com